Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosingBAUSS, Frieder; RUSSELL, R. Graham G.Osteoporosis international. 2004, Vol 15, Num 6, pp 423-433, issn 0937-941X, 11 p.Article

Effects of ibandronate on bone quality : Preclinical studiesBAUSS, F; DEMPSTER, D. W.Bone (New York, NY). 2007, Vol 40, Num 2, pp 265-273, issn 8756-3282, 9 p.Article

Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 yearsLAMY, O; SANDINI, L; PACHE, I et al.Journal of endocrinological investigation (Testo stampato). 2003, Vol 26, Num 8, pp 728-732, issn 0391-4097, 5 p.Article

Ibandronate : Un nouveau bisphosphonate par voie orale = Ibandronate : a new oral bisphosphonateThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 11, pp 55-56, issn 0253-8512, 2 p.Article

Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCTBOCK, Oliver; BORST, Hendrikje; BELLER, Gisela et al.Bone (New York, NY). 2012, Vol 50, Num 1, pp 317-324, issn 8756-3282, 8 p.Article

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trialHAKALA, M; KRÖGER, H; VALLEALA, H et al.Scandinavian journal of rheumatology. 2012, Vol 41, Num 4, pp 260-266, issn 0300-9742, 7 p.Article

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy : implications from clinical studies with ibandronatePAPAPOULOS, S. E; SCHIMMER, R. C.Postgraduate medical journal. 2008, Vol 84, Num 992, pp 307-312, issn 0032-5473, 6 p.Article

Ibandronate reduces skeletal morbidity in patients with breast cancer : IbandronateTRIPATHY, Debu; DIEL, Ingo; BODY, Jean-Jacques et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 64-66, issn 0093-7754, 3 p., SUP10Article

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment : Prediction of bone mass changes during treatmentRAVN, P; CHRISTENSEN, J. O; BAUMANN, M et al.Bone (New York, NY). 1998, Vol 22, Num 5, pp 559-564, issn 8756-3282Article

Intravenous ibandronate injections in postmenopausal women with osteoporosis : One-year results from the dosing intravenous administration studyDELMAS, Pierre D; ADAMI, Silvano; BOLOGNESE, Michael et al.Arthritis and rheumatism. 2006, Vol 54, Num 6, pp 1838-1846, issn 0004-3591, 9 p.Article

Once-monthly ibandronate for postmenopausal osteoporosis : Review of a new dosing regimenPYON, Eunice Y.Clinical therapeutics. 2006, Vol 28, Num 4, pp 475-490, issn 0149-2918, 16 p.Article

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE studyDELMAS, P. D; RECKER, R. R; CHESNUT, C. H et al.Osteoporosis international. 2004, Vol 15, Num 10, pp 792-798, issn 0937-941X, 7 p.Article

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisRECKER, R; STAKKESTAD, J. A; CHESNUT, C. H et al.Bone (New York, NY). 2004, Vol 34, Num 5, pp 890-899, issn 8756-3282, 10 p.Article

Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonatesSUNG JIN BAE; KIM, Beom-Jun; KYEONG HYE LIM et al.Journal of bone and mineral metabolism (English ed.). 2012, Vol 30, Num 5, pp 588-595, issn 0914-8779, 8 p.Article

Drug-drug interaction study between a novel oral ibandronate formulation and metforminBITTNER, Beate; MCINTYRE, Christine; JORDAN, Paul et al.Arzneimittel-Forschung. 2011, Vol 61, Num 12, issn 0004-4172, E707-E713Article

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA studyRECKER, Robert R; STE-MARIE, Louis-George; LANGDAHL, Bente et al.Bone (New York, NY). 2010, Vol 46, Num 3, pp 660-665, issn 8756-3282, 6 p.Article

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures : Results of a meta-analysisSEBBA, Anthony I; EMKEY, Ronald D; KOHLES, Joseph D et al.Bone (New York, NY). 2009, Vol 44, Num 3, pp 423-427, issn 8756-3282, 5 p.Article

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppressionBINKLEY, N; SILVERMAN, S. L; SIMONELLI, C et al.Osteoporosis international. 2009, Vol 20, Num 9, pp 1595-1601, issn 0937-941X, 7 p.Article

Efficacy and Tolerability of Intravenous Ibandronate Injections in Postmenopausal Osteoporosis : 2-Year Results from the DIVA StudyEISMAN, John A; CIVITELLI, Roberto; MAIRON, Nicole et al.Journal of rheumatology. 2008, Vol 35, Num 3, pp 488-497, issn 0315-162X, 10 p.Article

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy : implications from clinical studies with ibandronatePAPAPOULOS, S. E; SCHIMMER, R. C.Annals of the rheumatic diseases. 2007, Vol 66, Num 7, pp 853-858, issn 0003-4967, 6 p.Article

Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronateARMSTRONG, D. J; WRIGHT, S. A; COWARD, S. M et al.Annals of the rheumatic diseases. 2006, Vol 65, Num 7, pp 976-977, issn 0003-4967, 2 p.Article

Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapyRINGE, Johann D; FABER, Herbert; FARAHMAND, Parvis et al.Journal of bone and mineral metabolism (English ed.). 2006, Vol 24, Num 1, pp 87-93, issn 0914-8779, 7 p.Article

Analytical methods for the quantification of ibandronate in body fluids and boneENDELE, Richard; LOEW, Heiner; BAUSS, Frieder et al.Journal of pharmaceutical and biomedical analysis. 2005, Vol 39, Num 1-2, pp 246-256, issn 0731-7085, 11 p.Article

Biological properties and mechanism of action of ibandronate : Application to the treatment of osteoporosisEPSTEIN, S; ZAIDI, M.Bone (New York, NY). 2005, Vol 37, Num 4, pp 433-440, issn 8756-3282, 8 p.Article

Efficacy and safety of ibandronate given by intravenous injection once every 3 monthsADAMI, S; FELSENBERG, D; CHRISTIANSEN, C et al.Bone (New York, NY). 2004, Vol 34, Num 5, pp 881-889, issn 8756-3282, 9 p.Article